
    
      This Phase I/IIA, open label, multicenter, dose escalation study of CB-103 in patients with
      Advanced or Metastatic Solid Tumours and Haematological Malignancies. After providing signed
      informed consent, patients will be screened for entry into the study. The study will be
      conducted in 2 stages: dose escalation in Part A of the study followed by dose expansion in
      Part B (Phase IIA).

      Escalation cohorts will receive repeat doses of CB-103 to determine the MTD and RP2D.

      CB-103 will be administered orally on a once-daily schedule, based on a 28-day treatment
      cycle. Aim of the expansion Phase IIA, Part B of the study will be to collect preliminary
      evidence of anti-tumour activity.
    
  